Avidity Partners Management LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 28, 2026), Avidity Partners Management LP reported 45 stock positions worth $493.8 million. Its top holding was Dianthus Therapeutics (DNTH) at 35.8% of the portfolio, followed by CG Oncology (CGON, 17.7%) and Oruka Therapeutics (ORKA, 7.6%). Compared with Q4 2025, it opened 21 new positions, sold out of 15, added to 11 and reduced 10. The biggest buy was Perspective Therapeutics (CATX, shares +88%) and the biggest sale an exit from Alnylam Pharmaceuticals (ALNY).
- Most Recent 13F
- Q2 2026
- Location
- DALLAS, TX
- CIK
- 0001791827
- Portfolio Value
- $493.8M (Q1 2026)
- SEC Filing
- 0001791827-26-000004 ↗ filed May 28, 2026
Holdings Value
Holdings 45 stocks · $493.8M
| DNTH Dianthus Therapeutics Inc. | 35.76% | 2,104,184 | $176.6M | No change |
| CGON CG Oncology Inc. | 17.67% | 1,288,948 | $87.2M | Reduce -12.5% |
| ORKA Oruka Therapeutics Inc. | 7.55% | 760,424 | $37.3M | Add +15.1% |
| CATX Perspective Therapeutics Inc. | 5.11% | 6,049,999 | $25.2M | Add +88.4% |
| JBIO Jade Biosciences Inc. | 3.99% | 1,400,708 | $19.7M | No change |
| ELVN Enliven Therapeutics Inc. | 3.18% | 400,000 | $15.7M | Add +185.1% |
| TEVA Teva Pharmaceutical-SP ADR | 2.75% | 450,100 | $13.6M | Add +7.9% |
| CNTX Context Therapeutics Inc. | 2.65% | 4,998,267 | $13.1M | Reduce -9.2% |
| RGEN Repligen Corp. | 1.86% | 77,800 | $9.2M | Add +54.7% |
| PVLA Palvella Therapeutics Inc. | 1.77% | 70,000 | $8.7M | Add +262.7% |
| MDT Medtronic PLC | 1.75% | 100,000 | $8.7M | Reduce -7.1% |
| VIR Vir Biotechnology Inc. | 1.72% | 950,000 | $8.5M | New |
| AKTS Aktis Oncology Inc. | 1.70% | 468,566 | $8.4M | New |
| IMUX Immunic Inc. | 1.51% | 6,699,411 | $7.4M | Add +42.6% |
| DXCM Dexcom Inc. | 1.14% | 90,000 | $5.7M | New |
| EHC Encompass Health Corp. | 0.82% | 42,000 | $4.1M | Add +32.9% |
| BSX Boston Scientific Corp. | 0.76% | 60,000 | $3.8M | Reduce -47.6% |
| TENX Tenax Therapeutics Inc. | 0.70% | 215,934 | $3.5M | New |
| GILD Gilead Sciences Inc. | 0.56% | 20,000 | $2.8M | New |
| PHAT Phathom Pharmaceuticals Inc. | 0.56% | 249,390 | $2.8M | Add +21.0% |
| KPTI Karyopharm Therapeutics Inc. | 0.52% | 463,741 | $2.6M | Add +244.6% |
| CNC Centene Corp. | 0.46% | 70,000 | $2.3M | Reduce -41.4% |
| MSLE Satellos Bioscience Inc. | 0.44% | 387,769 | $2.2M | New |
| SCYX Scynexis Inc. | 0.39% | 2,081,660 | $1.9M | No change |
| NTRA Natera Inc. | 0.36% | 9,000 | $1.8M | Reduce -23.7% |
| ICLR Icon PLC | 0.36% | 16,000 | $1.8M | Reduce -51.7% |
| KVUE Kenvue Inc. | 0.35% | 100,000 | $1.7M | Reduce -57.0% |
| CRVS Corvus Pharmaceuticals Inc. | 0.34% | 115,000 | $1.7M | New |
| HIMS Hims & Hers Health Inc. | 0.32% | 75,000 | $1.6M | New |
| RVMD Revolution Medicines Inc. | 0.30% | 15,000 | $1.5M | New |
| GPCR Structure Therapeutics Inc. | 0.29% | 30,000 | $1.4M | New |
| GMAB Genmab A/S -SP ADR | 0.27% | 50,000 | $1.3M | Reduce -45.6% |
| CORT Corcept Therapeutics Inc. | 0.24% | 30,000 | $1.2M | Add +36.4% |
| TEM Tempus AI Inc. Class A | 0.23% | 25,000 | $1.1M | New |
| ABVX Abivax SA-ADR | 0.23% | 10,000 | $1.1M | New |
| UNH Unitedhealth Group Inc. | 0.21% | 3,800 | $1.0M | New |
| NTLA Intellia Therapeutics Inc. | 0.19% | 75,000 | $962K | New |
| ODD Oddity Tech Ltd. Class A | 0.19% | 70,000 | $937K | New |
| MLTX Moonlake Immunotherapeutics | 0.19% | 50,000 | $932K | New |
| PTON Peloton Interactive Inc. Class A | 0.17% | 200,000 | $858K | New |
| AVR Anteris Technologies Global | 0.17% | 150,000 | $833K | New |
| ABUS Arbutus Biopharma Corp. | 0.11% | 125,000 | $563K | New |
| BBOT Bridgebio Oncology Therapeut | 0.08% | 43,853 | $392K | New |
| ACAD Acadia Pharmaceuticals Inc. | 0.06% | 12,967 | $289K | Reduce -87.9% |
| TRVI Trevi Therapeutics Inc. | 0.02% | 6,660 | $79K | New |
Portfolio Sells Q4 2025 → Q1 2026
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −2.41 |
| BSX Boston Scientific Corp. | Reduce -47.6% | 0.76% | −2.39 |
| MCK McKesson Corp. | Sold out | 0.00% | −2.25 |
| A Agilent Technologies Inc. | Sold out | 0.00% | −1.63 |
| PFE Pfizer Inc. | Sold out | 0.00% | −1.46 |
| ICLR Icon PLC | Reduce -51.7% | 0.36% | −1.38 |
| MDT Medtronic PLC | Reduce -7.1% | 1.75% | −1.23 |
| DHR Danaher Corp. | Sold out | 0.00% | −1.12 |
| TMO Thermo Fisher Scientific Inc. | Sold out | 0.00% | −1.12 |
| NVO Novo-Nordisk A/S-Spons ADR | Sold out | 0.00% | −0.99 |
| CNC Centene Corp. | Reduce -41.4% | 0.46% | −0.95 |
| CI The Cigna Group | Sold out | 0.00% | −0.92 |
| COR Cencora Inc. | Sold out | 0.00% | −0.92 |
| INSM Insmed Inc. | Sold out | 0.00% | −0.89 |
| WAT Waters Corp. | Sold out | 0.00% | −0.89 |
| KVUE Kenvue Inc. | Reduce -57.0% | 0.35% | −0.81 |
| ACAD Acadia Pharmaceuticals Inc. | Reduce -87.9% | 0.06% | −0.77 |
| ACHC Acadia Healthcare Co. Inc. | Sold out | 0.00% | −0.69 |
| ITGR Integer Holdings Corp. | Sold out | 0.00% | −0.67 |
| GMAB Genmab A/S -SP ADR | Reduce -45.6% | 0.27% | −0.55 |
| HQY Healthequity Inc. | Sold out | 0.00% | −0.45 |
| NTRA Natera Inc. | Reduce -23.7% | 0.36% | −0.42 |
| IQV Iqvia Holdings Inc. | Sold out | 0.00% | −0.29 |
| CGON CG Oncology Inc. | Reduce -12.5% | 17.67% | +0.03 |
| CNTX Context Therapeutics Inc. | Reduce -9.2% | 2.65% | +0.32 |
Portfolio Buys Q4 2025 → Q1 2026
| CATX Perspective Therapeutics Inc. | Add +88.4% | 5.11% | +2.56 |
| ELVN Enliven Therapeutics Inc. | Add +185.1% | 3.18% | +2.55 |
| ORKA Oruka Therapeutics Inc. | Add +15.1% | 7.55% | +1.78 |
| VIR Vir Biotechnology Inc. | New | 1.72% | +1.72 |
| AKTS Aktis Oncology Inc. | New | 1.70% | +1.70 |
| PVLA Palvella Therapeutics Inc. | Add +262.7% | 1.77% | +1.18 |
| DXCM Dexcom Inc. | New | 1.14% | +1.14 |
| IMUX Immunic Inc. | Add +42.6% | 1.51% | +0.78 |
| TENX Tenax Therapeutics Inc. | New | 0.70% | +0.70 |
| GILD Gilead Sciences Inc. | New | 0.56% | +0.56 |
| MSLE Satellos Bioscience Inc. | New | 0.44% | +0.44 |
| CRVS Corvus Pharmaceuticals Inc. | New | 0.34% | +0.34 |
| HIMS Hims & Hers Health Inc. | New | 0.32% | +0.32 |
| RVMD Revolution Medicines Inc. | New | 0.30% | +0.30 |
| GPCR Structure Therapeutics Inc. | New | 0.29% | +0.29 |
| KPTI Karyopharm Therapeutics Inc. | Add +244.6% | 0.52% | +0.24 |
| TEM Tempus AI Inc. Class A | New | 0.23% | +0.23 |
| ABVX Abivax SA-ADR | New | 0.23% | +0.23 |
| UNH Unitedhealth Group Inc. | New | 0.21% | +0.21 |
| NTLA Intellia Therapeutics Inc. | New | 0.19% | +0.19 |
| ODD Oddity Tech Ltd. Class A | New | 0.19% | +0.19 |
| MLTX Moonlake Immunotherapeutics | New | 0.19% | +0.19 |
| PTON Peloton Interactive Inc. Class A | New | 0.17% | +0.17 |
| AVR Anteris Technologies Global | New | 0.17% | +0.17 |
| ABUS Arbutus Biopharma Corp. | New | 0.11% | +0.11 |
| BBOT Bridgebio Oncology Therapeut | New | 0.08% | +0.08 |
| CORT Corcept Therapeutics Inc. | Add +36.4% | 0.24% | +0.02 |
| TRVI Trevi Therapeutics Inc. | New | 0.02% | +0.02 |
| EHC Encompass Health Corp. | Add +32.9% | 0.82% | −0.14 |
| PHAT Phathom Pharmaceuticals Inc. | Add +21.0% | 0.56% | −0.42 |
| RGEN Repligen Corp. | Add +54.7% | 1.86% | −0.52 |
| TEVA Teva Pharmaceutical-SP ADR | Add +7.9% | 2.75% | −1.01 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 45 | $624.4M | DNTH, CGON, ORKA, JBIO, ELVN |
| Q1 2026Amended | 45 | $493.8M | DNTH, CGON, ORKA, CATX, JBIO |
| Q4 2025 | 39 | $346.7M | DNTH, CGON, JBIO, ORKA, TEVA |
| Q3 2025 | 43 | $439.4M | DNTH, CGON, MDT, BSX, ORKA |
| Q2 2025 | 55 | $498.8M | CGON, BSX, NTRA, DNTH, EXAS |
| Q1 2025 | 63 | $484.9M | BSX, DNTH, UNH, CGON, HUM |
| Q4 2024 | 61 | $1.0B | DNTH, BSX, JANX, NTRA, EXAS |
| Q3 2024 | 81 | $2.0B | BSX, DNTH, ISRG, NTRA, CGON |
| Q2 2024 | 84 | $2.4B | ISRG, BSX, NTRA, ARVN, ACHC |
| Q1 2024 | 86 | $2.8B | FUSN, BSX, ARVN, ISRG, DNTH |